Screener / SEC EDGAR /CIK 0001865782 /10-K filed Feb 27, 2026, compared with Mar 6, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Home Health Care Services

BrightSpring Health Services, Inc. BTSG

Compare with peers Embed
FY2025 at a glance

Sales up 28.2%, free cash flow up to $394.7M

XBRL, from each 10-K
RevenueStatements
$12.9B from $10.1B in FY2024
FY2022FY2025
Net incomeStatements
$190.7M from -$18.1M in FY2024
FY2022FY2025
Free cash flowStatements
$394.7M from -$57.1M in FY2024
FY2022FY2025
EPS (diluted)Statements
$0.87 from $-0.09 in FY2024
FY2022FY2025
Operating marginStatements
2.3% from 1.1% in FY2024
FY2022FY2025
Total debtStatements
$2.5B from $2.6B in FY2024
FY2022FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (40)
EPS (ttm)
1.86
Sales (ttm)
15.3B
Net income (ttm)
410.3M
Sales growth
+28.2%
EPS growth
-
Sales Q/Q
+26.4%
Free cash flow
492.4M
Gross margin
12.5%
Oper. margin
3.4%
Net margin
2.7%
FCF margin
3.2%
ROA
6.5%
R&D / sales
-
Dividend
-
Debt/Eq
1.00
Curr. ratio
1.62
Cash
717.8M
Op. cash flow (ttm)
602.7M
EBITDA
459.5M
EBITDA margin
3.6%
Net debt
1.5B
Quick ratio
1.14
Interest cover
1.88
ROIC
5.1%
FCF after stock pay
324.6M
Debt / FCF (years)
5.53
Goodwill / assets
39.7%
Tax rate
24.0%
Stock pay / sales
0.5%
Shares out.
199.0M
Shares Y/Y
+13.9%
Book / share
10.94
Cash / share
3.61
Sales / share
76.64
Asset turnover
2.43
Days sales out.
28
Sales 3Y CAGR
+18.7%
Employees
23,500
Sales / employee
649K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2022 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 12.9B +18.7% a year Net income 190.7M
FY2022 revenue 7.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-25-034196 FY2022 net income -53.9M · NetIncomeLoss, 0000950170-25-034196 7.7B FY2022 FY2023 revenue 7.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-079454 FY2023 net income -154.6M · NetIncomeLoss, 0001193125-26-079454 7.7B FY2023 FY2024 revenue 10.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-079454 FY2024 net income -18.1M · NetIncomeLoss, 0001193125-26-079454 10.1B FY2024 FY2025 revenue 12.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-079454 FY2025 net income 190.7M · NetIncomeLoss, 0001193125-26-079454 12.9B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2022 to FY2025 (3 years).

Growth per share, FY2022 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +10.0% a year FY2022 $6.41 to FY2025 $8.53, 3 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $0.87$8.53$1.80
Dec 31, 2024 -$0.09$8.54-$0.30
Dec 31, 2023 -$1.31$4.96$1.16
Dec 31, 2022 -$0.46$6.41-$0.63

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $2.9B
  • − All liabilities $4.5B
  • = Net current asset value -$1.6B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $1.9B
  • − Goodwill $2.5B
  • − Other intangible assets $557.6M
  • = Tangible book value -$1.2B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

BTSG against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+28.2%30th of 155 · median +10.5%
Net margin
-4.1%15.3%
2.7%93rd of 154 · median 6.8%
Return on equity
-5.2%18.5%
18.8%36th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
3.2%103rd of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
1.0076th of 108 · median 0.69
BTSG and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
BTSG BrightSpring Health Services, Inc.$15.3B +28.2%12.5%2.7%18.8%3.2%1.00
REGN Regeneron Pharmaceuticals$16.9B +1.0%-28.5%14.4%22.6%0.06
VTRS Viatris$14.7B -3.0%35.3%-4.1%-4.4%14.3%0.97
LH Labcorp$14.6B +7.2%29.0%6.9%11.3%8.8%0.66
DVA DaVita$14.2B +6.5%-6.5%-9.1%-
HSIC Henry Schein$13.7B +4.0%31.6%3.1%13.3%4.1%1.12
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by segment

From $12.9B of sales to $190.7M of profit FY2025

  • Pharmacy Solutions $11.4B
  • Provider Services $1.5B
Revenue to Gross profit: $1.5BRevenue to Cost of revenue: $11.4BGross profit to Operating profit: $295.3MGross profit to Operating expenses: $1.2BOperating profit to Net profit: $190.7MOperating profit to Tax & other: $104.6M Revenue: $12.9B REVENUE $12.9B +28% Y/Y Gross profit: $1.5B · 12% margin GROSS PROFIT $1.5B 12% margin · +20% Y/Y Cost of revenue: $11.4B · 88% of revenue COST OF REVENUE $11.4B 88% of revenue Operating profit: $295.3M · 2% margin OPERATING PROFIT $295.3M 2% margin · +173% Y/Y Operating expenses: $1.2B · 9% of revenue OPERATING EXPENSES $1.2B 9% of revenue Net profit: $190.7M · 1% margin NET PROFIT $190.7M 1% margin Tax & other: $104.6M · 1% of revenue TAX & OTHER $104.6M 1% of revenue

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2023 · 10-K XBRL, year-end balances

Return on equity 10.2% FY2023: -26.4% net income ÷ equity
Net margin 1.5% FY2023: -2.0% profit per $ of sales: 190.7M ÷ 12.9B
Asset turnover 2.01× FY2023: 1.39× sales per $ of assets: 12.9B ÷ 6.4B
Leverage 3.42× FY2023: 9.46× assets per $ of equity: 6.4B ÷ 1.9B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    2.7% vs 6.8%
  • Gross margin down over 3 years
    17.5% → 11.8%
  • Return on equity above 15%
    18.8%
  • A profit in 1 of 4 years
Net margin, FY2022 to FY2025: -0.7% to 1.5%

Balance sheet

  • Interest covered less than 5 times
    Operating income is 1.9× interest expense
  • Debt larger than equity
    Debt / equity 1.00 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 1.62
  • Net debt under 3 years of free cash flow
    $1.5B net debt, 3.0 years
Debt / equity at each year end, FY2022 to FY2025: 5.75 to 1.34

Cash and shareholders

  • Free cash flow positive in 2 of 4 years
    $394.7M last year
  • Share count up over 3 years
    +86.5%
  • Cash from operations above net income
    $490.2M vs $190.7M
Free cash flow, FY2022 to FY2025: -74.8M to 394.7M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$2.6B of principal due, schedule of Dec 31, 2025

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Deferred revenue, current part

Paid in advance $11.0M cash received before delivery, not yet recognized as revenue, Sep 30, 2026 · +33.0% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

BTSG's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 4. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue12.9B
FY2022: 7.7BFY2023: 7.7BFY2024: 10.1BFY2025: 12.9B FY2022FY2023FY2024FY2025
Net income190.7M
FY2022: -53.9MFY2023: -154.6MFY2024: -18.1MFY2025: 190.7M FY2022FY2023FY2024FY2025
Free cash flow394.7M
FY2022: -74.8MFY2023: 137.3MFY2024: -57.1MFY2025: 394.7M FY2022FY2023FY2024FY2025
Free cash flow after stock pay324.6M
FY2022: -78.3MFY2023: 133.3MFY2024: -126.3MFY2025: 324.6M FY2022FY2023FY2024FY2025
EPS (diluted)0.87
FY2022: -0.46FY2023: -1.31FY2024: -0.09FY2025: 0.87 FY2022FY2023FY2024FY2025
Diluted shares219.8M
FY2022: 117.8MFY2023: 117.9MFY2024: 193.0MFY2025: 219.8M FY2022FY2023FY2024FY2025

Revenue by business segment

year to Dec 31, 2025
RevenueSharevs year before
Pharmacy Solutions 11.4B88.7% +30.7%
Provider Services 1.5B11.3% +11.1%

10-K 0001193125-26-079454, segment and revenue notes (XBRL).

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Medicare Part D 4.1B31.7% +28.0%
Commercial Insurance 3.3B25.6% +30.7%
Medicare Part C 2.4B18.7% +44.9%
Medicaid 1.5B11.6% +28.2%
Medicare Part A 1.1B8.5% +9.5%
Private and Other 424.1M3.3% +2.2%
Medicare Part B 82.8M0.6% -13.7%

10-K 0001193125-26-079454, segment and revenue notes (XBRL).

Revenue by business segment, 4 years

from the segment notes of the last 2 10-Ks
FY2022FY2023FY2024FY2025
Pharmacy Solutions5.3B6.5B8.8B11.4B
Provider Services2.2B1.2B1.3B1.5B
Other274.7M---
Sum of segments7.7B7.7B10.1B12.9B

Revenue and operating income by business segment, as each 10-K reports them in its segment note (XBRL). Each year comes from the newest 10-K that reports it, so a year the company later recast shows the recast number; click a number to open that 10-K. Segments changed: FY2022 is in italics, as first reported under the earlier segments, so it is not comparable with the later years. Rows without a number were not reported as a separate segment that year. "Corporate and other" and "All other" are the 10-K's own lines for what is outside the segments.

Income statement

From EDGAR
FY2022FY2023FY2024FY2025
Revenue7.7B7.7B10.1B12.9B
Gross profit1.4B1.1B1.3B1.5B
SG&A1.1B1.1B1.2B1.2B
Operating income187.8M58.1M108.0M295.3M
Interest expense233.6M271.9M190.5M157.3M
Pretax income-45.8M-213.8M-95.3M137.9M
Income tax33.1M-31.5M-26.4M33.1M
Net income-53.9M-154.6M-18.1M190.7M
EPS (diluted)-0.46-1.31-0.090.87
Diluted shares117.8M117.9M193.0M219.8M
Depreciation & amortization204.0M202.3M204.5M164.3M
EBITDA391.8M260.5M312.4M459.5M
Gross margin17.5%14.8%12.6%11.8%
Operating margin2.4%0.8%1.1%2.3%
Net margin-0.7%-2.0%-0.2%1.5%
Revenue growth--0.4%+31.0%+28.2%

Balance sheet

From EDGAR
FY2022FY2023FY2024FY2025
Cash13.2M12.4M61.0M88.4M
Receivables-766.9M902.8M989.7M
Inventory-398.9M636.6M815.2M
Current assets-1.5B1.9B2.9B
Property & equipment-175.5M180.6M204.7M
Goodwill2.3B2.3B2.4B2.5B
Other intangible assets-640.3M595.2M557.6M
Total assets-5.5B5.9B6.4B
Accounts payable-624.8M923.9M1.2B
Current liabilities-1.2B1.4B1.8B
Total debt-3.4B2.6B2.5B
Total liabilities-4.9B4.3B4.5B
Shareholders' equity754.8M584.7M1.6B1.9B
Retained earnings--200.3M-222.2M-74.6M

Cash flow

From EDGAR
FY2022FY2023FY2024FY2025
Operating cash flow-4.7M210.8M23.8M490.2M
Capital spending70.1M73.5M80.9M95.5M
Free cash flow-74.8M137.3M-57.1M394.7M
Stock-based pay (added back)3.5M3.9M69.2M70.1M
Free cash flow after stock pay-78.3M133.3M-126.3M324.6M
Buybacks-650K650K43.2M
Acquisitions42.5M63.1M59.8M204.6M
Debt raised--2.6B-
Debt repaid40.7M30.4M3.4B50.3M
Investing cash flow45.4M-134.4M-140.2M-305.1M
Financing cash flow-73.8M-76.9M164.6M-157.9M

Stock-based pay and leases

From EDGAR
FY2022FY2023FY2024FY2025
Stock-based pay (expense)3.5M3.9M69.2M70.1M
Stock-based pay / revenue0.0%0.1%0.7%0.5%
Operating lease cost92.8M52.2M55.1M56.7M
Operating lease cash paid91.6M51.6M55.3M58.2M
Finance lease principal paid10.9M11.6M11.6M13.5M
Right-of-use assets-166.1M161.0M171.6M
Operating lease liabilities-171.8M168.4M178.4M
Finance lease liabilities--10.0M21.3M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BTSG/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.